Both Apellis Pharmaceuticals Inc. (NASDAQ:APLS) and UroGen Pharma Ltd. (NASDAQ:URGN) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.

Valuation and Earnings

Table 1 shows the gross revenue, earnings per share and valuation for Apellis Pharmaceuticals Inc. and UroGen Pharma Ltd.

Profitability

Table 2 shows us Apellis Pharmaceuticals Inc. and UroGen Pharma Ltd.’s return on equity, return on assets and net margins.

Liquidity

The Current Ratio of Apellis Pharmaceuticals Inc. is 15.2 while its Quick Ratio stands at 15.2. The Current Ratio of rival UroGen Pharma Ltd. is 7.6 and its Quick Ratio is has 7.6. Apellis Pharmaceuticals Inc. is better equipped to clear short and long-term obligations than UroGen Pharma Ltd.

Analyst Recommendations

The next table highlights the shown recommendations and ratings for Apellis Pharmaceuticals Inc. and UroGen Pharma Ltd.

The upside potential is 88.92% for Apellis Pharmaceuticals Inc. with average target price of $45. Competitively UroGen Pharma Ltd. has a consensus target price of $45.5, with potential upside of 38.47%. Based on the results shown earlier, Apellis Pharmaceuticals Inc. is looking more favorable than UroGen Pharma Ltd., analysts view.

Institutional & Insider Ownership

Apellis Pharmaceuticals Inc. and UroGen Pharma Ltd. has shares held by institutional investors as follows: 53.8% and 59.2%. 0.1% are Apellis Pharmaceuticals Inc.’s share held by insiders. On the other hand, insiders held about 1.3% of UroGen Pharma Ltd.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Apellis Pharmaceuticals Inc. had bullish trend while UroGen Pharma Ltd. had bearish trend.

Summary

Apellis Pharmaceuticals Inc. beats UroGen Pharma Ltd. on 6 of the 9 factors.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidates include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration, and chronic obstructive pulmonary disease. The company develops APL-2 for subcutaneous injection, which is an injection into the tissue under the skin, and for intravitreal injection that is an injection into the eye, as well as APL-1 for inhaled administration. Apellis Pharmaceuticals, Inc. was founded in 2009 and is based in Crestwood, Kentucky.

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are formulations of the chemotherapy drug Mitomycin C, a generic drug which is currently used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy. The company is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in RaÂ’anana, Israel.